Advertisement
Singapore markets close in 3 hours 21 minutes

  • Straits Times Index

    3,286.85
    -0.90 (-0.03%)
     

  • Nikkei

    38,039.75
    +411.27 (+1.09%)
     

  • Hang Seng

    17,688.62
    +404.08 (+2.34%)
     

  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     

  • Bitcoin USD

    64,340.45
    +112.57 (+0.18%)
     

  • CMC Crypto 200

    1,387.79
    +5.22 (+0.38%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • Dow

    38,085.80
    -375.12 (-0.98%)
     

  • Nasdaq

    15,611.76
    -100.99 (-0.64%)
     

  • Gold

    2,348.00
    +5.50 (+0.23%)
     

  • Crude Oil

    83.96
    +0.39 (+0.47%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • FTSE Bursa Malaysia

    1,573.86
    +4.61 (+0.29%)
     

  • Jakarta Composite Index

    7,115.99
    -39.31 (-0.55%)
     

  • PSE Index

    6,577.64
    +2.76 (+0.04%)
     

Gilead Sciences buying Forty Seven for $4.9 billion

Associated Press
Updated ·1-min read

Gilead Sciences is buying the cancer treatment company Forty Seven in a deal valued at approximately $4.9 billion.

Gilead, based in Foster City, California, will pay $95.50 for each Forty Seven Inc. share.

Gilead said Monday that the transaction will strengthen its immuno-oncology research and development portfolio with the addition of of Forty Seven Inc.'s investigational lead product candidate, magrolimab, which is in clinical development for the treatment of several cancers.

Forty Seven's stock soared more than 60% before the market open. Gilead rose 1.2%.

The deal is targeted to close in the second quarter.